Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Aug 25;4(16):3952-3959.
doi: 10.1182/bloodadvances.2020001963.

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up

Jorge J Castillo  1   2 , Kirsten Meid  1 , Catherine A Flynn  1 , Jiaji Chen  1 , Maria G Demos  1 , Maria L Guerrera  1 , Amanda Kofides  1 , Xia Liu  1 , Manit Munshi  1 , Nicholas Tsakmaklis  1 , Christopher J Patterson  1 , Guang Yang  1   2 , Zachary Hunter  1   2 , Steven P Treon  1   2
Affiliations
Clinical Trial

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up

Jorge J Castillo et al. Blood Adv. .

Abstract

Proteasome inhibition is a standard of care for the primary treatment of patients with Waldenström macroglobulinemia (WM). We present the long-term follow-up of a prospective, phase II clinical trial that evaluated the combination of ixazomib, dexamethasone, and rituximab (IDR) in 26 treatment-naive patients with WM. IDR was administered as 6 monthly induction cycles followed by 6 every-2-month maintenance cycles. The MYD88 L265P mutation was detected in all patients, and CXCR4 mutations were detected in 15 patients (58%). The median time to response (TTR) and time to major response (TTMR) were 2 and 6 months, respectively. Patients with and without CXCR4 mutations had median TTR of 3 months and 1 month, respectively (P = .003), and median TTMR of 10 months and 3 months, respectively (P = .31). The overall, major, and very good partial response (VGPR) rates were 96%, 77%, and 19%, respectively. The rate of VGPR in patients with and without CXCR4 mutations were 7% and 36%, respectively (P = .06). The median progression-free survival (PFS) was 40 months, the median duration of response (DOR) was 38 months, and the median time to next treatment (TTNT) was 40 months. PFS, DOR, and TTNT were not affected by CXCR4 mutational status. The safety profile was excellent with no grade 4 adverse events or deaths to date. IDR provides a safe and effective frontline treatment option for symptomatic patients with WM. This study was registered at www.clinicaltrials.gov as #NCT02400437.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.J.C. has received honoraria and/or research funds from AbbVie, Beigene, Janssen, Kymera, Millennium, Pharmacyclics, and TG Therapeutics. S.P.T. has received research funding and/or consulting fees from BMS, Pharmacyclics, and Janssen. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
CONSORT diagram. The patient excluded was found to have diffuse large B-cell lymphoma at screening.
Figure 2.
Figure 2.
Kaplan-Meier estimates for TTR and TTMR. Kaplan-Meier estimates for TTR for the entire cohort (A) and according to CXCR4 mutational status (B). TTMR for the entire cohort (C) and according to CXCR4 mutational status (D) of 26 patients with WM treated with IDR.
Figure 3.
Figure 3.
Response rates of 26 patients with WM treated with IDR according to CXCR4 mutational status. Major response rates were 93% and 100% for patients with and without CXCR4 mutations, respectively.
Figure 4.
Figure 4.
Kaplan-Meier estimates for PFS, DOR, and TTNT. Kaplan-Meier estimates for PFS for the entire cohort (A) and according to CXCR4 mutational status (B). DOR for the entire cohort (C) and according to CXCR4 mutational status (D). TTNT for the entire cohort (E) and according to CXCR4 mutational status (F) of 26 patients with WM treated with IDR.
See this image and copyright information in PMC

References

    1. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. . Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276-3282. - PubMed
    1. Ghobrial IM, Xie W, Padmanabhan S, et al. . Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol. 2010;85(9):670-674. - PubMed
    1. Treon SP, Ioakimidis L, Soumerai JD, et al. . Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830-3835. - PMC - PubMed
    1. Treon SP, Tripsas CK, Meid K, et al. . Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia. Blood. 2014;124(4):503-510. - PubMed
    1. Waxman AJ, Clasen S, Hwang WT, et al. . Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):e174519. - PMC - PubMed

Publication types

Associated data